Acrux Receives FDA Approval for Nitroglycerin Ointment and Secures $2.65 Million Funding

Key Insights

• Acrux Limited has gained FDA approval for its Nitroglycerin Ointment, marking a significant milestone for the company's product portfolio.
• The company has also secured $2.65 million through a share placement with institutional investors to bolster its market expansion efforts.
• A share purchase plan for eligible shareholders complements the funding round, further supporting Acrux's strategic initiatives in the pharmaceutical sector.

Acrux Limited has announced the FDA approval of its Nitroglycerin Ointment, accompanied by $2.65 million in funding secured through a share placement to institutional investors. This dual achievement underscores Acrux's strategic focus on expanding its presence in the pharmaceutical market.

The funding, coupled with a share purchase plan for eligible shareholders, is intended to support the commercialization and further development of Acrux's product pipeline. The FDA approval of the Nitroglycerin Ointment represents a key regulatory milestone for the company, paving the way for its introduction to the U.S. market.

Acrux intends to leverage this recent approval and financial injection to strengthen its market position and pursue additional opportunities within the pharmaceutical landscape. The company's strategic initiatives are designed to drive growth and enhance shareholder value through targeted investments and product development efforts.